- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07680816
Metabolic and Functional Study of γδ T Cells in Critically Ill Patients
16 september 2026 uppdaterad av: Jiancheng Zhang, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Subset-specific Metabolic Adaptation and Functional Remodeling of Gamma Delta T (γδ T) Cells in Critically Ill ICU Patients: A Single-center, Prospective, Observational Cohort Study.
This prospective observational cohort study investigates the subset-specific metabolic adaptation and functional remodeling of cytotoxic γδT cells in critically ill patients with and without sepsis.
Emerging evidence indicates that γδT cells, as a bridge between innate and adaptive immunity, play a critical role in early anti-infection defense during sepsis.
However, the functional status and underlying regulatory mechanisms of cytotoxic γδT cells in septic patients remain incompletely understood.
Our preliminary single-cell transcriptomic analysis revealed that cytotoxic γδT cells from septic patients exhibit significant alterations in cytotoxicity-associated molecules (GZMB, PRF1, GNLY) and mitochondrial oxidative phosphorylation (OXPHOS) pathway genes, particularly COX6C, which correlates with cytotoxic effector molecule expression.
This study aims to systematically characterize the proportion, cytotoxicity, and mitochondrial metabolic function of circulating cytotoxic γδT cells across three cohorts: healthy controls, critically ill non-septic patients, and critically ill septic patients.
By integrating flow cytometry, mitochondrial function assays, and functional validation experiments, we seek to elucidate the role of COX6C-mediated mitochondrial metabolic abnormalities in cytotoxic γδT cell dysfunction, providing theoretical basis for understanding immune dysregulation in sepsis and identifying novel therapeutic targets.
Studieöversikt
Status
Rekrytering
Studietyp
Observationell
Inskrivning (Beräknad)
105
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
Outside of the US
-
Wuhan, Outside of the US, Kina, 430022
- Rekrytering
- Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
Kontakt:
- Jiancheng Zhang, Dr.
- Telefonnummer: 13554105815
- E-post: zhjcheng1@126.com
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Ja
Testmetod
Icke-sannolikhetsprov
Studera befolkning
The study population comprises three distinct groups: healthy volunteers, non-septic critically ill patients, and septic critically ill patients admitted to the intensive care unit.
Sepsis is defined according to the Sepsis-3 criteria (infection with an acute increase in SOFA score ≥2 points), while critical illness is based on standard ICU admission criteria.
All participants must be aged ≥18 years and provide written informed consent (from the participant or a legally authorized representative for those unable to consent).
Key exclusion criteria include known immunodeficiency, recent use of T-cell-targeted immunosuppressants or immune checkpoint inhibitors, expected ICU stay <24 hours, pregnancy, active major bleeding, or inability to obtain consent.
Consecutive enrollment will take place at the Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, with follow-up through 90 days after enrollment.
Beskrivning
Inclusion Criteria:
Healthy Control Group (NHC):
- Age ≥ 18 years.
- No acute or chronic major diseases.
- Provide written informed consent.
Non-septic Critical Illness Group (CI-NS):
- Age ≥ 18 years.
- Admitted to the ICU and meeting the definition of critical illness.
- Excluded from sepsis according to the Sepsis-3 criteria (infection + ΔSOFA ≥ 2 points).
- Written informed consent provided by the participant or legally authorized representative.
Septic Critical Illness Group (CI-Sep):
- Age ≥ 18 years.
- Admitted to the ICU and meeting the Sepsis-3 criteria (infection + ΔSOFA ≥ 2 points).
- Written informed consent provided by the participant or legally authorized representative.
Exclusion Criteria:
- Age < 18 years.
- Known immunodeficiency, HIV infection, active hematologic malignancy, or history of hematopoietic stem cell or solid organ transplantation within the past 3 months.
- Receipt of T-cell-targeted immunosuppressive therapy (e.g., antithymocyte globulin, calcineurin inhibitors, mycophenolate mofetil, methotrexate, or high-dose corticosteroids >1 mg/kg/day prednisone equivalent) before ICU admission or within 24 hours after ICU admission.
- Use of immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1/CTLA-4 antibodies) within the past 6 weeks.
- Expected ICU stay < 24 hours or imminent risk of death (moribund state).
- Pregnancy or breastfeeding.
- Active major bleeding.
- Inability to obtain informed consent.
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
|---|
|
Healthy Controls (NHCs)
Healthy volunteers without acute or chronic major diseases, aged ≥18 years, who have provided written informed consent.
Participants undergo a single blood draw and rectal swab collection.
|
|
Critically Ill Non-Septic Patients (CI-NS)
Patients admitted to the ICU meeting the criteria for critical illness but without sepsis, as determined by the Sepsis-3 criteria (infection with ΔSOFA ≥ 2 points excluded).
Participants are aged ≥18 years, with informed consent obtained from the patient or legally authorized representative.
Blood and rectal swab samples are collected at three time points: within 24 hours of ICU admission (D0), Day 2 (D2), and Day 7 (D7).
Clinical follow-up extends to 90 days.
|
|
Critically Ill Septic Patients (CI-Sep)
Patients admitted to the ICU meeting the Sepsis-3 criteria (infection with ΔSOFA ≥ 2 points).
Participants are aged ≥18 years, with informed consent obtained from the patient or legally authorized representative.
Blood and rectal swab samples are collected at three time points: within 24 hours of ICU admission (D0), Day 2 (D2), and Day 7 (D7).
Clinical follow-up extends to 90 days.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in the Proportion of Cytotoxic γδT Cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺) Among Total γδT Cells
Tidsram: Day 2 post-ICU admission
|
Flow cytometric quantification of the frequency of Cytotoxic γδT cells, defined as TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺ cells, as a percentage of total γδT cells (TCRγδ⁺) in peripheral blood.
This subset represents the cytotoxic effector population critical for early anti-infection defense.
|
Day 2 post-ICU admission
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in COX6C Expression in Cytotoxic γδT Cells
Tidsram: Day 2 post-ICU admission
|
Measurement of COX6C (mitochondrial respiratory chain complex IV subunit) expression levels in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺) at the mRNA level (by single-cell RNA sequencing) and protein level (by flow cytometry).
|
Day 2 post-ICU admission
|
|
Change in Cytotoxic Molecule Expression in Cytotoxic γδT Cells
Tidsram: Day 2 post-ICU admission
|
Flow cytometric quantification of the mean fluorescence intensity (MFI) of cytotoxic effector molecules including Granzyme B (GZMB), Perforin (PRF1), and Granulysin (GNLY) in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺).
|
Day 2 post-ICU admission
|
|
Change in Mitochondrial Mass in Cytotoxic γδT Cell
Tidsram: Day 2 post-ICU admission
|
Flow cytometric quantification of mitochondrial mass using MitoTracker Green FM staining in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺).
|
Day 2 post-ICU admission
|
|
Change in Mitochondrial Membrane Potential (TMRE) in Cytotoxic γδT Cells
Tidsram: Day 2 post-ICU admission
|
Flow cytometric quantification of mitochondrial membrane potential using tetramethylrhodamine ethyl ester (TMRE) staining in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺).
|
Day 2 post-ICU admission
|
|
Change in Mitochondrial Membrane Potential (JC-1) in Cytotoxic γδT Cells
Tidsram: Day 2 post-ICU admission
|
Flow cytometric quantification of mitochondrial membrane potential using JC-1 dye (red/green fluorescence ratio) in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺).
|
Day 2 post-ICU admission
|
|
Change in Oxygen Consumption Rate (OCR) in Cytotoxic γδT Cells
Tidsram: Day 2 post-ICU admission
|
Measurement of basal oxygen consumption rate reflecting oxidative phosphorylation (OXPHOS) capacity in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺).
|
Day 2 post-ICU admission
|
|
Change in Extracellular Acidification Rate (ECAR) in Cytotoxic γδT Cells
Tidsram: Day 2 post-ICU admission
|
Measurement of basal extracellular acidification rate reflecting glycolytic metabolic activity in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺).
|
Day 2 post-ICU admission
|
|
Change in Glycolytic Capacity of Cytotoxic γδT Cells at Serial Time Points
Tidsram: Day 0, Day 2, and Day 7 post-ICU admission
|
Longitudinal flow cytometric puromycin-incorporation assay (SCENITH method) to measure glycolytic capacity in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺) at Day 0, Day 2, and Day 7 post-ICU admission, to track the temporal evolution of metabolic flexibility and stress-adaptive glycolytic reprogramming during the course of critical illness.
|
Day 0, Day 2, and Day 7 post-ICU admission
|
|
Change in Mitochondrial ROS Levels in Cytotoxic γδT Cells at Serial Time Points
Tidsram: Day 0, Day 2, and Day 7 post-ICU admission
|
Longitudinal flow cytometric quantification of mitochondrial reactive oxygen species (mitochondrial ROS) levels using MitoSOX Green staining in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺) at Day 0, Day 2, and Day 7 post-ICU admission, reflecting oxidative stress dynamics.
|
Day 0, Day 2, and Day 7 post-ICU admission
|
|
Change in Cytotoxic γδT Cell Migratory Function
Tidsram: Day 2 post-ICU admission
|
Assessment of Cytotoxic γδT cell (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺) chemotactic and migratory capacity using Transwell migration assay.
|
Day 2 post-ICU admission
|
|
Change in Total γδT Cell Proportion at Serial Time Points
Tidsram: Day 0, Day 2, and Day 7 post-ICU admission
|
Longitudinal flow cytometric quantification of the frequency of total γδT cells (TCRγδ⁺) as a percentage of total live CD3⁺ T cells in peripheral blood at Day 0, Day 2, and Day 7 post-ICU admission.
|
Day 0, Day 2, and Day 7 post-ICU admission
|
|
Change in Cytotoxic γδT Cell Proportion at Serial Time Points
Tidsram: Day 0, Day 2, and Day 7 post-ICU admission
|
Longitudinal flow cytometric quantification of the frequency of Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺) as a percentage of total γδT cells at Day 0, Day 2, and Day 7 post-ICU admission, to track the temporal evolution of this cell subset.
|
Day 0, Day 2, and Day 7 post-ICU admission
|
|
Change in COX6C Expression in Cytotoxic γδT Cells at Serial Time Points
Tidsram: Day 0, Day 2, and Day 7 post-ICU admission
|
Longitudinal measurement of COX6C expression levels in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺) at Day 0, Day 2, and Day 7 post-ICU admission, to assess the temporal dynamics of mitochondrial metabolic gene expression.
|
Day 0, Day 2, and Day 7 post-ICU admission
|
|
Correlation Between Cytotoxic γδT Cell Glycolytic Capacity and APACHE II Score
Tidsram: Day 2 post-ICU admission
|
Spearman rank correlation analysis between glycolytic capacity (measured by puromycin incorporation assay at Day 2) in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺) with APACHE II (Acute Physiology and Chronic Health Evaluation II) score measured within the first 48 hours of ICU admission.
|
Day 2 post-ICU admission
|
|
Correlation Between Cytotoxic γδT Cell Glycolytic Capacity and SOFA Score
Tidsram: Day 2 post-ICU admission
|
Spearman rank correlation analysis between glycolytic capacity (measured by puromycin incorporation assay at Day 2) in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺) with SOFA (Sequential Organ Failure Assessment) score measured within the first 48 hours of ICU admission.
|
Day 2 post-ICU admission
|
|
Correlation Between Cytotoxic γδT Cell Metabolic Parameters and vasopressor dose
Tidsram: Day 2 post-ICU admission
|
Correlation analysis between COX6C expression, glycolytic capacity, and mitochondrial ROS levels in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺) with vasopressor dose (reported as norepinephrine equivalent dose, NEE).
|
Day 2 post-ICU admission
|
|
Correlation Between Cytotoxic γδT Cell Metabolic Parameters and plasma lactate levels
Tidsram: Day 2 post-ICU admission
|
Correlation analysis between COX6C expression, glycolytic capacity, and mitochondrial ROS levels in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺) with plasma lactate levels.
|
Day 2 post-ICU admission
|
|
Association Between Cytotoxic γδT Cell Glycolytic Capacity and 28-day all-cause mortality
Tidsram: Up to 90 days post-discharge
|
Analysis of association between glycolytic capacity (measured at Day 2) in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺) and 28-day all-cause mortality.
Patients will be stratified by vital status (survivors vs. non-survivors) and by hospital length of stay (above vs. below median) for comparative analysis.
|
Up to 90 days post-discharge
|
|
Association Between Cytotoxic γδT Cell Glycolytic Capacity and 90-day all-cause mortality
Tidsram: Up to 90 days post-discharge
|
Analysis of association between glycolytic capacity (measured at Day 2) in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺) and 90-day all-cause mortality.
Patients will be stratified by vital status (survivors vs. non-survivors) and by hospital length of stay (above vs. below median) for comparative analysis.
|
Up to 90 days post-discharge
|
|
Association Between Cytotoxic γδT Cell Glycolytic Capacity and in-hospital mortality
Tidsram: Up to 90 days post-discharge
|
Analysis of association between glycolytic capacity (measured at Day 2) in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺) and in-hospital mortality.
Patients will be stratified by vital status (survivors vs. non-survivors) and by hospital length of stay (above vs. below median) for comparative analysis.
|
Up to 90 days post-discharge
|
|
Association Between Cytotoxic γδT Cell Glycolytic Capacity and ICU mortality
Tidsram: Up to 90 days post-discharge
|
Analysis of association between glycolytic capacity (measured at Day 2) in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺) and ICU mortality.
Patients will be stratified by vital status (survivors vs. non-survivors) and by hospital length of stay (above vs. below median) for comparative analysis.
|
Up to 90 days post-discharge
|
|
Association Between Cytotoxic γδT Cell Glycolytic Capacity and hospital length of stay
Tidsram: Up to 90 days post-discharge
|
Analysis of association between glycolytic capacity (measured at Day 2) in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺) and hospital length of stay (days).
Patients will be stratified by vital status (survivors vs. non-survivors) and by hospital length of stay (above vs. below median) for comparative analysis.
|
Up to 90 days post-discharge
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Faktisk)
21 juni 2026
Primärt slutförande (Beräknad)
15 april 2027
Avslutad studie (Beräknad)
15 juli 2027
Studieregistreringsdatum
Först inskickad
25 juni 2026
Först inskickad som uppfyllde QC-kriterierna
1 juli 2026
Första postat (Faktisk)
2 juli 2026
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
17 september 2026
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
16 september 2026
Senast verifierad
1 september 2026
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- zjc202612
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Nej
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .